Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SERETIDE Rotacaps · 2 trials · 1 indication
Area under the plasma fluticasone propionate concentration-time curve over dosing interval; maximum concentration for fluticasone propionate and salmeterol plasma concentration-time curve on the last day of each study treatment period (Day 4).
Blood samples of participants (par.) with asthma and chronic obstructive pulmonary disease (COPD) were collected and analyzed for AUC(0-tau), a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (12 hours). Asthma is a disorder that causes the airways of the lungs to swell and narrow, leading to difficulty in breathing. COPD is a chronic lung disease with structural changes in lungs, leading to difficulty in breathing.
Participants' blood samples were collected and analyzed for SC levels. Weighted mean SC levels are evaluted as a measure of the degree of cortisol suppression, allowing for the determination of whether differences in systemic exposure to the inhaled steroid component of two devices can be significant enough to result in the differences in the body's ability to release cortisol. Weighted means were derived by calculating the AUC over the 0-12 hour period, using the linear trapezoidal rule (statistical technique used for numerical analysis) and then dividing it by the actual time interval.
| Arm | Type | Description |
|---|---|---|
| SERETIDE Rotacaps | EXPERIMENTAL | Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a capsule-based inhaler (Rotahaler). Devices with varying airflow resistance, low, intermediate and high, will be used. |
| SERETIDE Diskus | ACTIVE_COMPARATOR | Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a multi-dose dry powder inhaler |
| Placebo Rotacaps | PLACEBO_COMPARATOR | Placebo delivered in a capsule-based inhaler |
| Placebo Diskus | PLACEBO_COMPARATOR | Placebo delivered in a multi-dose dry powder inhaler |
| Name | Type | Description |
|---|---|---|
| SERETIDE Rotacaps | DRUG | The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4. |
| SERETIDE Diskus | DRUG | The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4. |
INCLUSION CRITERIA: A subject will be eligible for inclusion in this study only if all of the following criteria apply: * ALT, alkaline phosphatase and bilirubin less than or equal to 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * Si...
SERETIDE Rotacaps is an investigational small molecule being developed for asthma. It is a capsule-based dry powder inhaler formulation of fluticasone propionate and salmeterol. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
SERETIDE Rotacaps combines fluticasone propionate, a corticosteroid, and salmeterol, a long-acting beta-agonist. These components work together to reduce inflammation and relax airway muscles in asthma patients. The drug is delivered via a capsule-based inhaler device.
SERETIDE Rotacaps is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in asthma patients.
SERETIDE Rotacaps is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. Two Phase 1 trials have been completed, with a total of 96 participants enrolled across studies in Australia and New Zealand.
SERETIDE Rotacaps has been studied in two completed Phase 1 trials. NCT01494610 evaluated the drug in 60 patients with moderate asthma and moderate to severe COPD. NCT01540708 assessed the Rotacap formulation and ROTAHALER device in 36 healthy volunteers.
SERETIDE Rotacaps is a combination product containing fluticasone propionate and salmeterol, delivered in a capsule-based inhaler. It is being developed as an alternative to multi-dose dry powder inhalers for asthma treatment. The drug is currently in Phase 1 trials.